This study tests the safety, tolerability and efficacy of an intravenous dose of ALD403, a genetically-engineered anti-CGRP, for the prevention of migraine. 

In the study, published in The Lancet Neurology, David W. Dodick, MD, of the Mayo Clinic in Arizona, and colleagues, administered either 1,000 mg dose of ALD403 or placebo to 163 randomly-assigned patients aged 18 to 55 years who had five to 14 migraine days per 28-day period to assess the drug’s safety, tolerability, and efficacy.

READ FULL ARTICLE Curated publisher From Thelancet